2 days ago
July 28 (Reuters) - Apple's market capitalization briefly surpassed $5 trillion for the first time on Tuesday, making it only the second company ever to achieve that milestone after Nvidia.
Its shares were last up 0.72% at $339.33, giving it a market capitalization of $4.98 trillion. At a session high of $342.89, Apple's market value stood at $5.036 trillion.
Apple became the most valuable company in the world earlier this month, overtaking chipmaker Nvidia - which had been at the top since June 2025 and was the first company ever to breach the $5 trillion threshold.
Nvidia's shares were last up 0.53% at $197.63, valuing it at $4.78 trillion.
Apple has benefited from strong demand for its products as well as its decision to skip the ongoing AI spending race among Big Tech rivals that is sapping their cash flows and saddling them with humongous debt.
#company
Its shares were last up 0.72% at $339.33, giving it a market capitalization of $4.98 trillion. At a session high of $342.89, Apple's market value stood at $5.036 trillion.
Apple became the most valuable company in the world earlier this month, overtaking chipmaker Nvidia - which had been at the top since June 2025 and was the first company ever to breach the $5 trillion threshold.
Nvidia's shares were last up 0.53% at $197.63, valuing it at $4.78 trillion.
Apple has benefited from strong demand for its products as well as its decision to skip the ongoing AI spending race among Big Tech rivals that is sapping their cash flows and saddling them with humongous debt.
#company
7 days ago
This article was originally published on ETFTrends.com.
International stocks are performing admirably this year. As of July 22, the MSCI ACWI ex-US Investable Market Index, which combines developed and emerging market equities, is higher by 11.51%. Sounds good and it is, but investors should dig deeper.
Artificial intelligence (AI)-adjacent and technology stocks, many hailing from emerging markets, have been key contributors to international equity upside this year. As a result, markets such as South Korea and Taiwan loom large in some supposedly diverse international ETFs. Plus, some of those funds now devote significant percentages of their portfolios to growth stocks.
For investors looking to defray some of those risks while adding more value exposure to their portfolios, the ALPS O'Shares International Developed Quality Dividend ETF (OEFA) is an idea to consider. With its emphasis on quality traits and dividend growth, OEFA could be an ideal complement to growth-heavy portfolios and for investors looking for a more prudent way to gain international exposure.
With the S&P 500 heavily allocated to AI-related stocks and with the same becoming true of some developing markets, developed market exposure – attainable via OEFA – becomes all the more compelling because the sector-level profiles in many developed markets don't resemble those found here in the U.S.
#international #stocks #market
International stocks are performing admirably this year. As of July 22, the MSCI ACWI ex-US Investable Market Index, which combines developed and emerging market equities, is higher by 11.51%. Sounds good and it is, but investors should dig deeper.
Artificial intelligence (AI)-adjacent and technology stocks, many hailing from emerging markets, have been key contributors to international equity upside this year. As a result, markets such as South Korea and Taiwan loom large in some supposedly diverse international ETFs. Plus, some of those funds now devote significant percentages of their portfolios to growth stocks.
For investors looking to defray some of those risks while adding more value exposure to their portfolios, the ALPS O'Shares International Developed Quality Dividend ETF (OEFA) is an idea to consider. With its emphasis on quality traits and dividend growth, OEFA could be an ideal complement to growth-heavy portfolios and for investors looking for a more prudent way to gain international exposure.
With the S&P 500 heavily allocated to AI-related stocks and with the same becoming true of some developing markets, developed market exposure – attainable via OEFA – becomes all the more compelling because the sector-level profiles in many developed markets don't resemble those found here in the U.S.
#international #stocks #market
8 days ago
This article was originally published on ETFTrends.com.
According to Bankrate's Mortgage Rates, the national average for a 30-year fixed mortgage is 6.61%. That's uncomfortably high and a major headwind to many prospective homebuyers, particularly those in the first-time category. But it's not all bad news in the mortgage market. Confirming opportunity abounds for fixed income investors with ETFs such as the WisdomTree Mortgage Plus Bond Fund (MTGP), some experts view mortgage-backed securities (MBS) as one of the more fundamentally sturdy corners of the bond market.
The actively managed MTGP, which turns seven years old in November, sports a 30-day SEC yield of 4.31%. That's impressive when considering the scant credit risk typically ***** ociated with MBS. The case for the WisdomTree ETF is fortified by a robust fundamental outlook.
"Agency mortgage-backed securities fundamentals remain supported by a combination of elevated mortgage rates, limited refinancing incentives, constrained housing turnover, and low net supply," noted BNP Paribas.
As noted above, high mortgage rates are drags on residential real estate activity. Those rates are barriers to entry for many buyers, which morphs into a problem for sellers. However, that situation can be a boon for MBS.
#market
According to Bankrate's Mortgage Rates, the national average for a 30-year fixed mortgage is 6.61%. That's uncomfortably high and a major headwind to many prospective homebuyers, particularly those in the first-time category. But it's not all bad news in the mortgage market. Confirming opportunity abounds for fixed income investors with ETFs such as the WisdomTree Mortgage Plus Bond Fund (MTGP), some experts view mortgage-backed securities (MBS) as one of the more fundamentally sturdy corners of the bond market.
The actively managed MTGP, which turns seven years old in November, sports a 30-day SEC yield of 4.31%. That's impressive when considering the scant credit risk typically ***** ociated with MBS. The case for the WisdomTree ETF is fortified by a robust fundamental outlook.
"Agency mortgage-backed securities fundamentals remain supported by a combination of elevated mortgage rates, limited refinancing incentives, constrained housing turnover, and low net supply," noted BNP Paribas.
As noted above, high mortgage rates are drags on residential real estate activity. Those rates are barriers to entry for many buyers, which morphs into a problem for sellers. However, that situation can be a boon for MBS.
#market
14 days ago
If you're a carrier operating in today's freight market, with tight margins, rate volatility, and rising operating costs, the real issue isn't the tool. It's whether the financing actually fits how your trucking business runs day to day.
Because in trucking, survival comes down to one thing: keeping cash moving at the same speed as freight.
Every carrier deals with the same basic cash flow problem:
Fuel, payroll, insurance, and maintenance are immediate and unavoidable expenses.
Revenue is generated load by load.
Because in trucking, survival comes down to one thing: keeping cash moving at the same speed as freight.
Every carrier deals with the same basic cash flow problem:
Fuel, payroll, insurance, and maintenance are immediate and unavoidable expenses.
Revenue is generated load by load.
15 days ago
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple.
On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company's Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company's current President, has been appointed as the new CEO and Director, who will take charge from July 7 onwards.
anyaivanova/Shutterstock.com
The company shared that Casale has over 25 years of experience, covering the biopharma segment and commercial leadership roles. He has prior experience working as the Chief Commercial Officer with Dynavax Technologies, where he played a pivotal role in scaling up the annual revenues for hepatitis B cure, HEPLISAV-B(R), to more than $300 million. He helped the vaccine achieve more than 50% market share across the U.S. market prior to the acquisition of the company by Sanofi for $2.2 billion.
Back on June 24, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) shared an update on the payer access for neffy, which is an epinephrine nasal spray. Based on the latest feedback, no new coverage decisions or commercial formulary inclusions have been released for neffy during the July 1 cycle.
On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company's Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company's current President, has been appointed as the new CEO and Director, who will take charge from July 7 onwards.
anyaivanova/Shutterstock.com
The company shared that Casale has over 25 years of experience, covering the biopharma segment and commercial leadership roles. He has prior experience working as the Chief Commercial Officer with Dynavax Technologies, where he played a pivotal role in scaling up the annual revenues for hepatitis B cure, HEPLISAV-B(R), to more than $300 million. He helped the vaccine achieve more than 50% market share across the U.S. market prior to the acquisition of the company by Sanofi for $2.2 billion.
Back on June 24, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) shared an update on the payer access for neffy, which is an epinephrine nasal spray. Based on the latest feedback, no new coverage decisions or commercial formulary inclusions have been released for neffy during the July 1 cycle.
18 days ago
Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy.
On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material to the employees' acceptance of employment with Geron.
The stock options have an exercise price of $1.23 per share, equal to the closing price of Geron's common stock on the grant date. The options have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of the employee's employment commencement and the remaining shares vesting over the following 42 months in equal installments, subject to continued employment.
15 States with the Best Healthcare in the US
Earlier in June, Geron Corporation (NASDAQ:GERN) announced that members of its management team were scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material to the employees' acceptance of employment with Geron.
The stock options have an exercise price of $1.23 per share, equal to the closing price of Geron's common stock on the grant date. The options have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of the employee's employment commencement and the remaining shares vesting over the following 42 months in equal installments, subject to continued employment.
15 States with the Best Healthcare in the US
Earlier in June, Geron Corporation (NASDAQ:GERN) announced that members of its management team were scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
20 days ago
A Qualified Charitable Distribution lets retirees transfer up to $111,000 directly from an IRA to charity, satisfying the RMD with zero taxable income.
2026 tax law changes cap cash charitable deductions at $1,000 for non-itemizers, making QCDs far more tax-efficient than traditional donate-and-deduct strategies.
Keeping RMD income off your AGI via a QCD can also prevent Medicare IRMAA surcharges, which trigger above $109,000 for individuals.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Required minimum distributions ambush retirees. You spent decades building your traditional IRA, and now the IRS demands you pull money out whether you need it or not. That forced income can push you into a higher bracket, raise your Medicare premiums, and increase the share of your Social Security benefits that gets taxed. If you already donate to charity, there is a fully legal, IRS-sanctioned way to satisfy your RMD without that money ever touching your tax return.
2026 tax law changes cap cash charitable deductions at $1,000 for non-itemizers, making QCDs far more tax-efficient than traditional donate-and-deduct strategies.
Keeping RMD income off your AGI via a QCD can also prevent Medicare IRMAA surcharges, which trigger above $109,000 for individuals.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Required minimum distributions ambush retirees. You spent decades building your traditional IRA, and now the IRS demands you pull money out whether you need it or not. That forced income can push you into a higher bracket, raise your Medicare premiums, and increase the share of your Social Security benefits that gets taxed. If you already donate to charity, there is a fully legal, IRS-sanctioned way to satisfy your RMD without that money ever touching your tax return.
20 days ago
We recently published Jim Cramer Insisted Recent AI Chip Selloff Wasn't A Bottom & Discussed These 17 Stocks. Lam Research Corporation (NASDAQ:LRCX) is one of the stocks discussed by Jim Cramer.
Lam Research Corporation (NASDAQ:LRCX) is one of the largest semiconductor manufacturing equipment providers in the world. Its shares are up by 233% over the past year and by 79% year-to-date. Susquehanna increased Lam Research Corporation (NASDAQ:LRCX)'s share price target to $475 from $385 and kept a Positive rating on the stock on June 30th. In its coverage, the financial firm discussed the backlog for semiconductor manufacturing equipment and remarked that it appeared to have extended beyond the one year mark. With Lam Research Corporation (NASDAQ:LRCX)'s shares gaining 2.7% on Wednesday, Cramer tweeted about the firm:
"The action in Lam Research, at the heart of the intellectual property when it comes to the data center away from Nvidia, is quite positive
Broadcom and Lam great tells today!
For illustration purposes only. Photo from Pixabay/Pexels
Lam Research Corporation (NASDAQ:LRCX) is one of the largest semiconductor manufacturing equipment providers in the world. Its shares are up by 233% over the past year and by 79% year-to-date. Susquehanna increased Lam Research Corporation (NASDAQ:LRCX)'s share price target to $475 from $385 and kept a Positive rating on the stock on June 30th. In its coverage, the financial firm discussed the backlog for semiconductor manufacturing equipment and remarked that it appeared to have extended beyond the one year mark. With Lam Research Corporation (NASDAQ:LRCX)'s shares gaining 2.7% on Wednesday, Cramer tweeted about the firm:
"The action in Lam Research, at the heart of the intellectual property when it comes to the data center away from Nvidia, is quite positive
Broadcom and Lam great tells today!
For illustration purposes only. Photo from Pixabay/Pexels
21 days ago
July 9 (Reuters) - OpenAI's CEO of AGI deployment Fidji Simo said on Thursday she will step down from her full-time role and pivot to a part-time advisory position at the ChatGPT maker, following an extended medical leave for a neuroimmune condition.
"Three months ago, I had to go on medical leave after a severe exacerbation of a chronic illness I've lived with for seven years. During that time, it became clear that the road to recovery would be much longer and more complex than I had anticipated - and that I needed to focus on it fully," Simo said in a post on X.
Simo, previously chief executive of Instacart and the head of the Facebook app at Meta, was among the three directors that joined OpenAI's board in March 2024 after Sam Altman returned as CEO.
"I am really sad about this and very grateful for all Fidji has done for OpenAI, and even grateful for her friendship and who she is as a person," Altman said in an X post.
Simo's exit from the senior role also comes as OpenAI gears up to go public amid insatiable demand for the technology.
"Three months ago, I had to go on medical leave after a severe exacerbation of a chronic illness I've lived with for seven years. During that time, it became clear that the road to recovery would be much longer and more complex than I had anticipated - and that I needed to focus on it fully," Simo said in a post on X.
Simo, previously chief executive of Instacart and the head of the Facebook app at Meta, was among the three directors that joined OpenAI's board in March 2024 after Sam Altman returned as CEO.
"I am really sad about this and very grateful for all Fidji has done for OpenAI, and even grateful for her friendship and who she is as a person," Altman said in an X post.
Simo's exit from the senior role also comes as OpenAI gears up to go public amid insatiable demand for the technology.
